Bristol─Myers Squibb announces positive results from phase 3 CheckMate ─214 trial of Opdivo plus low─dose Yervoy in patients with advanced RCC

Bristol─Myers Squibb Company announced patient─reported outcomes data from the phase 3 CheckMate ─214 trial in intermediate─ and poor─risk patients with advanced renal cell carcinoma (RCC) treated with the Immuno─Oncology combination Opdivo

More From BioPortfolio on "Bristol─Myers Squibb announces positive results from phase 3 CheckMate ─214 trial of Opdivo plus low─dose Yervoy in patients with advanced RCC"